Advancing targeted protein
degradation to target previously
“undruggable” disease pathways

Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016

Novel biologic therapeutics for
autoimmune diseases – Sold to
Celgene (NASDAQ: CELG) Jan 2017

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

First-in-class
RNA therapies
for severe genetic diseases

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

Precision therapeutics for
genetically-defined age-related
macular degeneration and rare diseases

Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)

Unlocking nature’s regulatory
mechanisms to fuel the
discovery of new medicines

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

Discovering new medicines
for severe
neurodegenerative diseases

Restoring metabolic balance
to treat NASH and other
serious metabolic diseases

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

Next generation
synthetic biology platform
for novel therapeutics

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

Small molecule
drug design
using statistical modeling

Next-generation antibody therapies
targeting the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)

Novel bicyclic peptides (bicycles)
and bicycle drug conjugates
for cancer

Bispecific antibodies
to improve the treatment
of serious diseases

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

Precision neuroscience to
treat neurological and
neuropsychiatric disease

Universal cell-based
cancer immunotherapy
IPO Mar 2018 (NASDAQ: UMRX)

Enhancing synaptic integrity
for treatment of
neurologic disorders

Breakthrough computer-aided
drug design
for transformative medicines

New class of
regulated cell and
gene therapies

Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)

Stimulating the innate and
adaptive immune system in a
novel approach to treat cancer

Proprietary pharmaceuticals for
neonatal care and pediatrics –
Sold to Mallinckrodt Aug 2017

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

Minimally invasive
heart valve
devices

Titratable, re-dosable genetic
medicines with drug-like properties
for patients with genetic diseases

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

Novel MetAP2 therapeutics to transform
complex metabolic disorders –
IPO June 2014 (NASDAQ: ZFGN)

Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

Cell and gene therapies for
rare diseases and cancer
IPO Jun 2018 (NASDAQ: AVRO)

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

Novel therapeutics
targeting
diseases of aging

Innovative micro-RNA-
based therapies –
IPO Feb 2017 (NASDAQ: MGEN)

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

Tamper resistant therapies for
chronic pain – IPO Feb 2014
(NASDAQ: EGLT)

Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016

Targeting RNA-modifying
proteins for novel
precision cancer therapies

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007

Preventing axonal degeneration
in patients with
neurological diseases